Strong Neutralizing Antibody Responses to SARS-CoV-2 Variants Following a Single Vaccine Dose in Subjects With Previous SARS-CoV-2 Infection
Abstract Background Previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection primes the immune system; thus individuals who have recovered from infection have enhanced immune responses to subsequent vaccination (hybrid immunity). However, it remains unclear how well hybrid imm...
Saved in:
Published in | Open forum infectious diseases Vol. 9; no. 12; p. ofac625 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
US
Oxford University Press
01.12.2022
|
Subjects | |
Online Access | Get full text |
ISSN | 2328-8957 2328-8957 |
DOI | 10.1093/ofid/ofac625 |
Cover
Loading…
Abstract | Abstract
Background
Previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection primes the immune system; thus individuals who have recovered from infection have enhanced immune responses to subsequent vaccination (hybrid immunity). However, it remains unclear how well hybrid immunity induced by severe or mild infection can cross-neutralize emerging variants. We aimed to compare the strength and breadth of antibody responses in vaccinated recovered and uninfected subjects.
Methods
We measured spike-specific immunoglobulin (Ig)G and neutralizing antibodies (NAbs) from vaccinated subjects including 320 with hybrid immunity and 20 without previous infection. From 29 subjects with a previous severe or mild infection, we also measured NAb responses against Alpha (B.1.1.7), Beta (B.1.351), Delta (B.1.617.2), and Omicron (B.1.1.529/BA.1) variants following vaccination.
Results
A single vaccine dose induced 2-fold higher anti-spike IgG concentrations and up to 4-fold higher neutralizing potency of antibodies in subjects with a previous infection compared with vaccinated subjects without a previous infection. Hybrid immunity was more enhanced after a severe than a mild infection, with sequentially decreasing NAb titers against Alpha, Beta, Delta, and Omicron variants. We found similar IgG concentrations in subjects with a previous infection after 1 or 2 vaccine doses.
Conclusions
Hybrid immunity induced strong IgG responses, particularly after severe infection. However, the NAb titers were low against heterologous variants, especially against Omicron. |
---|---|
AbstractList | Previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection primes the immune system; thus individuals who have recovered from infection have enhanced immune responses to subsequent vaccination (hybrid immunity). However, it remains unclear how well hybrid immunity induced by severe or mild infection can cross-neutralize emerging variants. We aimed to compare the strength and breadth of antibody responses in vaccinated recovered and uninfected subjects.BackgroundPrevious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection primes the immune system; thus individuals who have recovered from infection have enhanced immune responses to subsequent vaccination (hybrid immunity). However, it remains unclear how well hybrid immunity induced by severe or mild infection can cross-neutralize emerging variants. We aimed to compare the strength and breadth of antibody responses in vaccinated recovered and uninfected subjects.We measured spike-specific immunoglobulin (Ig)G and neutralizing antibodies (NAbs) from vaccinated subjects including 320 with hybrid immunity and 20 without previous infection. From 29 subjects with a previous severe or mild infection, we also measured NAb responses against Alpha (B.1.1.7), Beta (B.1.351), Delta (B.1.617.2), and Omicron (B.1.1.529/BA.1) variants following vaccination.MethodsWe measured spike-specific immunoglobulin (Ig)G and neutralizing antibodies (NAbs) from vaccinated subjects including 320 with hybrid immunity and 20 without previous infection. From 29 subjects with a previous severe or mild infection, we also measured NAb responses against Alpha (B.1.1.7), Beta (B.1.351), Delta (B.1.617.2), and Omicron (B.1.1.529/BA.1) variants following vaccination.A single vaccine dose induced 2-fold higher anti-spike IgG concentrations and up to 4-fold higher neutralizing potency of antibodies in subjects with a previous infection compared with vaccinated subjects without a previous infection. Hybrid immunity was more enhanced after a severe than a mild infection, with sequentially decreasing NAb titers against Alpha, Beta, Delta, and Omicron variants. We found similar IgG concentrations in subjects with a previous infection after 1 or 2 vaccine doses.ResultsA single vaccine dose induced 2-fold higher anti-spike IgG concentrations and up to 4-fold higher neutralizing potency of antibodies in subjects with a previous infection compared with vaccinated subjects without a previous infection. Hybrid immunity was more enhanced after a severe than a mild infection, with sequentially decreasing NAb titers against Alpha, Beta, Delta, and Omicron variants. We found similar IgG concentrations in subjects with a previous infection after 1 or 2 vaccine doses.Hybrid immunity induced strong IgG responses, particularly after severe infection. However, the NAb titers were low against heterologous variants, especially against Omicron.ConclusionsHybrid immunity induced strong IgG responses, particularly after severe infection. However, the NAb titers were low against heterologous variants, especially against Omicron. Previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection primes the immune system; thus individuals who have recovered from infection have enhanced immune responses to subsequent vaccination (hybrid immunity). However, it remains unclear how well hybrid immunity induced by severe or mild infection can cross-neutralize emerging variants. We aimed to compare the strength and breadth of antibody responses in vaccinated recovered and uninfected subjects. We measured spike-specific immunoglobulin (Ig)G and neutralizing antibodies (NAbs) from vaccinated subjects including 320 with hybrid immunity and 20 without previous infection. From 29 subjects with a previous severe or mild infection, we also measured NAb responses against Alpha (B.1.1.7), Beta (B.1.351), Delta (B.1.617.2), and Omicron (B.1.1.529/BA.1) variants following vaccination. A single vaccine dose induced 2-fold higher anti-spike IgG concentrations and up to 4-fold higher neutralizing potency of antibodies in subjects with a previous infection compared with vaccinated subjects without a previous infection. Hybrid immunity was more enhanced after a severe than a mild infection, with sequentially decreasing NAb titers against Alpha, Beta, Delta, and Omicron variants. We found similar IgG concentrations in subjects with a previous infection after 1 or 2 vaccine doses. Hybrid immunity induced strong IgG responses, particularly after severe infection. However, the NAb titers were low against heterologous variants, especially against Omicron. Background Previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection primes the immune system; thus individuals who have recovered from infection have enhanced immune responses to subsequent vaccination (hybrid immunity). However, it remains unclear how well hybrid immunity induced by severe or mild infection can cross-neutralize emerging variants. We aimed to compare the strength and breadth of antibody responses in vaccinated recovered and uninfected subjects. Methods We measured spike-specific immunoglobulin (Ig)G and neutralizing antibodies (NAbs) from vaccinated subjects including 320 with hybrid immunity and 20 without previous infection. From 29 subjects with a previous severe or mild infection, we also measured NAb responses against Alpha (B.1.1.7), Beta (B.1.351), Delta (B.1.617.2), and Omicron (B.1.1.529/BA.1) variants following vaccination. Results A single vaccine dose induced 2-fold higher anti-spike IgG concentrations and up to 4-fold higher neutralizing potency of antibodies in subjects with a previous infection compared with vaccinated subjects without a previous infection. Hybrid immunity was more enhanced after a severe than a mild infection, with sequentially decreasing NAb titers against Alpha, Beta, Delta, and Omicron variants. We found similar IgG concentrations in subjects with a previous infection after 1 or 2 vaccine doses. Conclusions Hybrid immunity induced strong IgG responses, particularly after severe infection. However, the NAb titers were low against heterologous variants, especially against Omicron. Abstract Background Previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection primes the immune system; thus individuals who have recovered from infection have enhanced immune responses to subsequent vaccination (hybrid immunity). However, it remains unclear how well hybrid immunity induced by severe or mild infection can cross-neutralize emerging variants. We aimed to compare the strength and breadth of antibody responses in vaccinated recovered and uninfected subjects. Methods We measured spike-specific immunoglobulin (Ig)G and neutralizing antibodies (NAbs) from vaccinated subjects including 320 with hybrid immunity and 20 without previous infection. From 29 subjects with a previous severe or mild infection, we also measured NAb responses against Alpha (B.1.1.7), Beta (B.1.351), Delta (B.1.617.2), and Omicron (B.1.1.529/BA.1) variants following vaccination. Results A single vaccine dose induced 2-fold higher anti-spike IgG concentrations and up to 4-fold higher neutralizing potency of antibodies in subjects with a previous infection compared with vaccinated subjects without a previous infection. Hybrid immunity was more enhanced after a severe than a mild infection, with sequentially decreasing NAb titers against Alpha, Beta, Delta, and Omicron variants. We found similar IgG concentrations in subjects with a previous infection after 1 or 2 vaccine doses. Conclusions Hybrid immunity induced strong IgG responses, particularly after severe infection. However, the NAb titers were low against heterologous variants, especially against Omicron. |
Author | Haveri, Anu Österlund, Pamela Lempainen, Johanna Melin, Merit Nieminen, Tuomo Palmu, Arto A Julkunen, Ilkka Ivaska, Lauri Tähtinen, Paula A Virta, Camilla Nohynek, Hanna Jalkanen, Pinja Ekström, Nina Solastie, Anna |
Author_xml | – sequence: 1 givenname: Nina surname: Ekström fullname: Ekström, Nina email: nina.ekstrom@thl.fi – sequence: 2 givenname: Anu surname: Haveri fullname: Haveri, Anu – sequence: 3 givenname: Anna surname: Solastie fullname: Solastie, Anna – sequence: 4 givenname: Camilla surname: Virta fullname: Virta, Camilla – sequence: 5 givenname: Pamela surname: Österlund fullname: Österlund, Pamela – sequence: 6 givenname: Hanna surname: Nohynek fullname: Nohynek, Hanna – sequence: 7 givenname: Tuomo surname: Nieminen fullname: Nieminen, Tuomo – sequence: 8 givenname: Lauri surname: Ivaska fullname: Ivaska, Lauri – sequence: 9 givenname: Paula A surname: Tähtinen fullname: Tähtinen, Paula A – sequence: 10 givenname: Johanna surname: Lempainen fullname: Lempainen, Johanna – sequence: 11 givenname: Pinja surname: Jalkanen fullname: Jalkanen, Pinja – sequence: 12 givenname: Ilkka surname: Julkunen fullname: Julkunen, Ilkka – sequence: 13 givenname: Arto A surname: Palmu fullname: Palmu, Arto A – sequence: 14 givenname: Merit surname: Melin fullname: Melin, Merit |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36519113$$D View this record in MEDLINE/PubMed |
BookMark | eNp9ks9vFCEUx4mpsT9vng2JBz10LAwwDJcmm9Vqk0ZNR-uRMAzTspmFFZg29W_oHy2T3Zq1iV54vLzP--Z94e2DHeedAeAlRu8wEuTE97bLh9JVyZ6BvZKUdVELxne27rvgKMYFQghjxBAXL8AuqRgWGJM98NCk4N01_GzGFNRgf9mczFyyre_u4aWJK--iiTB52Mwum2Lur4oSXqlglUsRnvlh8HdTj4JNDoPJNa2tM_C9jwZaB5uxXRid2R823cCvwdxaP8ZttXPXZ8B6dwie92qI5mgTD8D3sw_f5p-Kiy8fz-ezi0JTSlNBSbZOCK0F7mjNlepbxBFGigpuOKKqLylhvO-QQGVVc20q3CHNuSZUqFaQA3C61l2N7dJ02rjJu1wFu1ThXnpl5d8VZ2_ktb-VglPGa5QF3m4Egv85mpjk0kZthkE5k83JkjNasxoLmtHXT9CFH4PL9iTBHGNeMT4Jvtqe6M8ojx-VgXIN6OBjDKaX2iY1PVoe0A4SIzkthJwWQm4WIjcdP2l61P0H_maN-3H1f_I3PGLGBQ |
CitedBy_id | crossref_primary_10_22207_JPAM_18_3_48 crossref_primary_10_3390_diagnostics14070720 crossref_primary_10_3390_biom13101452 crossref_primary_10_3389_fimmu_2023_1152695 crossref_primary_10_1007_s10517_023_05951_7 |
Cites_doi | 10.1038/s41586-022-04778-y 10.1016/j.ebiom.2021.103656 10.1002/eji.202149535 10.1126/science.abh1282 10.1001/jama.2021.11656 10.3389/fimmu.2022.916686 10.1186/s12967-021-03208-3 10.1038/s41586-021-03696-9 10.1038/s41467-021-24285-4 10.1016/j.xcrm.2021.100486 10.2807/1560-7917.ES.2020.25.11.2000266 10.1038/s41591-022-01715-4 10.1001/jama.2021.15125 10.1016/j.ijid.2021.08.052 10.1056/NEJMc2101667 10.1038/s43856-022-00130-7 10.1128/Spectrum.01131-21 10.1128/mBio.00902-21 10.1038/s41591-021-01325-6 10.1056/NEJMoa2119497 10.1056/NEJMoa2027906 10.1016/S2666-5247(21)00275-5 10.1016/j.chom.2021.01.014 10.1001/jama.2021.3341 10.1016/S1473-3099(22)00140-2 10.3390/v14040802 10.1126/science.abg9175 10.1021/acs.jcim.1c01451 10.1126/sciimmunol.abn8014 10.1002/eji.202149785 10.1016/j.cell.2022.01.011 10.1016/S1473-3099(22)00143-8 10.1016/S0140-6736(21)00527-4 10.1016/S0140-6736(21)00501-8 10.1016/j.isci.2022.103743 10.1016/S0140-6736(21)00502-X 10.1126/sciimmunol.abi6950 10.1371/journal.pone.0263942 10.1038/s41467-022-28544-w 10.1001/jama.2021.22898 10.1128/mBio.02656-21 |
ContentType | Journal Article |
Copyright | The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2022 The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2022 – notice: The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. – notice: The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | TOX AAYXX CITATION NPM 3V. 7X7 7XB 8C1 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU COVID DWQXO FYUFA GHDGH K9. M0S PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
DOI | 10.1093/ofid/ofac625 |
DatabaseName | Oxford Journals Open Access Collection CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Public Health Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College Coronavirus Research Database ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Public Health ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic PubMed Publicly Available Content Database |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: TOX name: Oxford Journals Open Access Collection url: https://academic.oup.com/journals/ sourceTypes: Publisher – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2328-8957 |
ExternalDocumentID | PMC9745780 36519113 10_1093_ofid_ofac625 10.1093/ofid/ofac625 |
Genre | Journal Article |
GrantInformation_xml | – fundername: ; – fundername: ; grantid: 336410, 336431 – fundername: ; grantid: 5360-cc2fc |
GroupedDBID | 0R~ 53G 5VS 7X7 8C1 8FI 8FJ AAFWJ AAMVS AAPXW AAVAP ABDBF ABEJV ABGNP ABPTD ABUWG ABXVV ACGFS ACUHS ADBBV ADHZD ADPDF ADRAZ AENZO AFKRA AFPKN ALMA_UNASSIGNED_HOLDINGS ALUQC AMNDL AOIJS BAWUL BAYMD BCNDV BENPR CCPQU CIDKT DIK EBS EJD FYUFA GROUPED_DOAJ H13 HMCUK HYE IAO IHR ITC KQ8 KSI M48 M~E O9- OAWHX OJQWA OK1 OVD OVEED PEELM PIMPY ROL RPM TEORI TJX TOX UKHRP AAYXX CITATION PHGZM PHGZT AAPPN AFULF BTTYL NPM ROX 3V. 7XB 8FK AZQEC COVID DWQXO K9. PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
ID | FETCH-LOGICAL-c444t-43093334891d487aafb07010a497e704af24357fd0902687ce61d0c77c349ab93 |
IEDL.DBID | BENPR |
ISSN | 2328-8957 |
IngestDate | Thu Aug 21 18:39:32 EDT 2025 Fri Jul 11 09:09:41 EDT 2025 Fri Jul 25 21:39:49 EDT 2025 Wed Feb 19 02:26:14 EST 2025 Tue Jul 01 00:49:16 EDT 2025 Thu Apr 24 22:52:41 EDT 2025 Wed Apr 02 07:03:21 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 12 |
Keywords | previous infection neutralizing antibodies SARS-CoV-2 variants of concern hybrid immunity |
Language | English |
License | This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. https://creativecommons.org/licenses/by/4.0 The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c444t-43093334891d487aafb07010a497e704af24357fd0902687ce61d0c77c349ab93 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Potential conflicts of interest. The Finnish Institute for Health and Welfare conducts a Public-Private Partnership with vaccine manufacturers and has received research funding for studies unrelated to COVID-19 from GlaxoSmithKline Vaccines (N.E., C.V., A.A.P., and M.M. as investigators), Pfizer (A.A.P.), and Sanofi Pasteur (A.A.P., T.N.). The other authors report no potential conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. |
OpenAccessLink | https://www.proquest.com/docview/3171176570?pq-origsite=%requestingapplication% |
PMID | 36519113 |
PQID | 3171176570 |
PQPubID | 7089189 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_9745780 proquest_miscellaneous_2754858194 proquest_journals_3171176570 pubmed_primary_36519113 crossref_citationtrail_10_1093_ofid_ofac625 crossref_primary_10_1093_ofid_ofac625 oup_primary_10_1093_ofid_ofac625 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2022-12-01 |
PublicationDateYYYYMMDD | 2022-12-01 |
PublicationDate_xml | – month: 12 year: 2022 text: 2022-12-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | US |
PublicationPlace_xml | – name: US – name: United States – name: Oxford |
PublicationTitle | Open forum infectious diseases |
PublicationTitleAlternate | Open Forum Infect Dis |
PublicationYear | 2022 |
Publisher | Oxford University Press |
Publisher_xml | – name: Oxford University Press |
References | Liu (2022121311132761200_ofac625-B5) 2021; 29 Rusanen (2022121311132761200_ofac625-B26) 2021; 12 Haveri (2022121311132761200_ofac625-B3) 2022; 52 Cerqueira-Silva (2022121311132761200_ofac625-B20) 2022; 22 Walls (2022121311132761200_ofac625-B34) 2022; 185 Vicenti (2022121311132761200_ofac625-B17) 2021; 112 Saadat (2022121311132761200_ofac625-B28) 2021; 325 Bates (2022121311132761200_ofac625-B33) 2022; 327 Bobrovitz (2022121311132761200_ofac625-B40) Walsh (2022121311132761200_ofac625-B43) 2020; 383 Bates (2022121311132761200_ofac625-B44) 2021; 326 Hammerman (2022121311132761200_ofac625-B18) 2022; 386 Singh (2022121311132761200_ofac625-B42) Siracusano (2022121311132761200_ofac625-B11) 2022; 20 Stamatatos (2022121311132761200_ofac625-B35) 2021; 372 van Gils MJ (2022121311132761200_ofac625-B32) 2021; 3 Chen (2022121311132761200_ofac625-B6) 2022; 62 Marcotte (2022121311132761200_ofac625-B2) 2022; 25 Nordström (2022121311132761200_ofac625-B19) 2022; 22 Angyal (2022121311132761200_ofac625-B10) 2022; 3 Bates (2022121311132761200_ofac625-B14) 2022; 7 Wratil (2022121311132761200_ofac625-B37) 2022; 28 Goel (2022121311132761200_ofac625-B15) 2021; 6 Ontañón (2022121311132761200_ofac625-B8) 2021; 73 Zou (2022121311132761200_ofac625-B4) 2022; 13 Prendecki (2022121311132761200_ofac625-B29) 2021; 397 Miyamoto (2022121311132761200_ofac625-B38) 2022; 3 Reynolds (2022121311132761200_ofac625-B30) 2021; 372 Steensels (2022121311132761200_ofac625-B9) 2021; 326 Wang (2022121311132761200_ofac625-B31) 2021; 595 Muecksch (2022121311132761200_ofac625-B36) 2022; 607 Haveri (2022121311132761200_ofac625-B25) 2020; 25 Kristiansen (2022121311132761200_ofac625-B24) 2021; 397 Ebinger (2022121311132761200_ofac625-B7) 2021; 27 Jalkanen (2022121311132761200_ofac625-B21) 2021; 12 Nguyen P (2022121311132761200_ofac625-B22) 2022; 2 Haveri (2022121311132761200_ofac625-B1) 2021; 51 Lee (2022121311132761200_ofac625-B41) 2022; 13 Ibarrondo (2022121311132761200_ofac625-B13) 2021; 12 Stouten (2022121311132761200_ofac625-B39) 2022; 14 Romero-Ibarguengoitia (2022121311132761200_ofac625-B12) 2022; 17 Solastie (2022121311132761200_ofac625-B23) 2021; 9 Manisty (2022121311132761200_ofac625-B27) 2021; 397 Krammer (2022121311132761200_ofac625-B16) 2021; 384 |
References_xml | – volume: 607 start-page: 128 year: 2022 ident: 2022121311132761200_ofac625-B36 article-title: Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost publication-title: Nature doi: 10.1038/s41586-022-04778-y – volume: 73 start-page: 103656 year: 2021 ident: 2022121311132761200_ofac625-B8 article-title: Influence of past infection with SARS-CoV-2 on the response to the BNT162b2 mRNA vaccine in health care workers: kinetics and durability of the humoral immune response publication-title: EBioMedicine doi: 10.1016/j.ebiom.2021.103656 – volume: 51 start-page: 3202 year: 2021 ident: 2022121311132761200_ofac625-B1 article-title: Persistence of neutralizing antibodies a year after SARS-CoV-2 infection in humans publication-title: Eur J Immunol doi: 10.1002/eji.202149535 – volume: 372 start-page: 1418 year: 2021 ident: 2022121311132761200_ofac625-B30 article-title: Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose publication-title: Science doi: 10.1126/science.abh1282 – volume: 326 start-page: 868 year: 2021 ident: 2022121311132761200_ofac625-B44 article-title: Age-dependent neutralization of SARS-CoV-2 and P.1 variant by vaccine immune serum samples publication-title: JAMA doi: 10.1001/jama.2021.11656 – volume: 13 start-page: 916686 year: 2022 ident: 2022121311132761200_ofac625-B41 article-title: Prior vaccination exceeds prior infection in eliciting innate and humoral immune responses in Omicron infected outpatients publication-title: Front Immunol doi: 10.3389/fimmu.2022.916686 – volume: 20 start-page: 22 year: 2022 ident: 2022121311132761200_ofac625-B11 article-title: Different decay of antibody response and VOC sensitivity in naïve and previously infected subjects at 15 weeks following vaccination with BNT162b2 publication-title: J Transl Med doi: 10.1186/s12967-021-03208-3 – volume: 595 start-page: 426 year: 2021 ident: 2022121311132761200_ofac625-B31 article-title: Naturally enhanced neutralizing breadth to SARS-CoV-2 after one year publication-title: Nature doi: 10.1038/s41586-021-03696-9 – volume: 12 start-page: 3991 year: 2021 ident: 2022121311132761200_ofac625-B21 article-title: COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants publication-title: Nat Commun doi: 10.1038/s41467-021-24285-4 – volume: 3 start-page: 100486 year: 2021 ident: 2022121311132761200_ofac625-B32 article-title: A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern publication-title: Cell Rep Med doi: 10.1016/j.xcrm.2021.100486 – volume: 25 start-page: 2000266 year: 2020 ident: 2022121311132761200_ofac625-B25 article-title: Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020 publication-title: Euro Surveill doi: 10.2807/1560-7917.ES.2020.25.11.2000266 – volume: 3 start-page: 249 year: 2022 ident: 2022121311132761200_ofac625-B38 article-title: Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants publication-title: Med (N Y) – volume: 28 start-page: 496 year: 2022 ident: 2022121311132761200_ofac625-B37 article-title: Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern publication-title: Nat Med doi: 10.1038/s41591-022-01715-4 – volume: 326 start-page: 1533 year: 2021 ident: 2022121311132761200_ofac625-B9 article-title: Comparison of SARS-CoV-2 antibody response following vaccination with BNT162b2 and mRNA-1273 publication-title: JAMA doi: 10.1001/jama.2021.15125 – volume: 112 start-page: 40 year: 2021 ident: 2022121311132761200_ofac625-B17 article-title: Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose publication-title: Int J Infect Dis doi: 10.1016/j.ijid.2021.08.052 – ident: 2022121311132761200_ofac625-B40 article-title: Protective effectiveness of prior SARS-CoV-2 infection and hybrid immunity against Omicron infection and severe disease: a systematic review and meta-regression publication-title: MedRxiv – volume: 384 start-page: 1372 year: 2021 ident: 2022121311132761200_ofac625-B16 article-title: Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine publication-title: N Engl J Med doi: 10.1056/NEJMc2101667 – volume: 2 start-page: 65 year: 2022 ident: 2022121311132761200_ofac625-B22 article-title: The phylodynamics of SARS-CoV-2 during 2020 in Finland publication-title: Commun Med (Lond) doi: 10.1038/s43856-022-00130-7 – volume: 9 start-page: e0113121 year: 2021 ident: 2022121311132761200_ofac625-B23 article-title: A highly sensitive and specific SARS-CoV-2 spike- and nucleoprotein-based fluorescent multiplex immunoassay (FMIA) to measure IgG, IgA, and IgM class antibodies publication-title: Microbiol Spectr doi: 10.1128/Spectrum.01131-21 – volume: 12 start-page: e00902 year: 2021 ident: 2022121311132761200_ofac625-B26 article-title: A generic, scalable, and rapid time-resolved Förster resonance energy transfer-based assay for antigen detection-SARS-CoV-2 as a proof of concept publication-title: mBio doi: 10.1128/mBio.00902-21 – volume: 27 start-page: 981 year: 2021 ident: 2022121311132761200_ofac625-B7 article-title: Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2 publication-title: Nat Med doi: 10.1038/s41591-021-01325-6 – volume: 386 start-page: 1221 year: 2022 ident: 2022121311132761200_ofac625-B18 article-title: Effectiveness of the BNT162b2 vaccine after recovery from COVID-19 publication-title: N Engl J Med doi: 10.1056/NEJMoa2119497 – volume: 383 start-page: 2439 year: 2020 ident: 2022121311132761200_ofac625-B43 article-title: Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates publication-title: N Engl J Med doi: 10.1056/NEJMoa2027906 – volume: 3 start-page: e21 year: 2022 ident: 2022121311132761200_ofac625-B10 article-title: T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study publication-title: Lancet Microbe doi: 10.1016/S2666-5247(21)00275-5 – volume: 29 start-page: 477 year: 2021 ident: 2022121311132761200_ofac625-B5 article-title: Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization publication-title: Cell Host Microbe doi: 10.1016/j.chom.2021.01.014 – volume: 325 start-page: 1467 year: 2021 ident: 2022121311132761200_ofac625-B28 article-title: Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2 publication-title: JAMA doi: 10.1001/jama.2021.3341 – volume: 22 start-page: 791 year: 2022 ident: 2022121311132761200_ofac625-B20 article-title: Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(22)00140-2 – volume: 14 start-page: 802 year: 2022 ident: 2022121311132761200_ofac625-B39 article-title: Incidence and risk factors of COVID-19 vaccine breakthrough infections: a prospective cohort study in Belgium publication-title: Viruses doi: 10.3390/v14040802 – volume: 372 start-page: 1413 year: 2021 ident: 2022121311132761200_ofac625-B35 article-title: MRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection publication-title: Science doi: 10.1126/science.abg9175 – volume: 62 start-page: 412 year: 2022 ident: 2022121311132761200_ofac625-B6 article-title: Omicron variant (B.1.1.529): infectivity, vaccine breakthrough, and antibody resistance publication-title: J Chem Inf Model doi: 10.1021/acs.jcim.1c01451 – volume: 7 start-page: eabn8014 year: 2022 ident: 2022121311132761200_ofac625-B14 article-title: Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants publication-title: Sci Immunol doi: 10.1126/sciimmunol.abn8014 – volume: 52 start-page: 816 year: 2022 ident: 2022121311132761200_ofac625-B3 article-title: Neutralizing antibodies to SARS-CoV-2 Omicron variant after third mRNA vaccination in health care workers and elderly subjects publication-title: Eur J Immunol doi: 10.1002/eji.202149785 – volume: 185 start-page: 872 year: 2022 ident: 2022121311132761200_ofac625-B34 article-title: SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses publication-title: Cell doi: 10.1016/j.cell.2022.01.011 – volume: 22 start-page: 781 year: 2022 ident: 2022121311132761200_ofac625-B19 article-title: Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(22)00143-8 – volume: 397 start-page: 1347 year: 2021 ident: 2022121311132761200_ofac625-B24 article-title: WHO international standard for anti-SARS-CoV-2 immunoglobulin publication-title: Lancet doi: 10.1016/S0140-6736(21)00527-4 – volume: 397 start-page: 1057 year: 2021 ident: 2022121311132761200_ofac625-B27 article-title: Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals publication-title: Lancet doi: 10.1016/S0140-6736(21)00501-8 – volume: 25 start-page: 103743 year: 2022 ident: 2022121311132761200_ofac625-B2 article-title: Immunity to SARS-CoV-2 up to 15 months after infection publication-title: iScience doi: 10.1016/j.isci.2022.103743 – volume: 397 start-page: 1178 year: 2021 ident: 2022121311132761200_ofac625-B29 article-title: Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine publication-title: Lancet doi: 10.1016/S0140-6736(21)00502-X – volume: 6 start-page: eabi6950 year: 2021 ident: 2022121311132761200_ofac625-B15 article-title: Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination publication-title: Sci Immunol doi: 10.1126/sciimmunol.abi6950 – ident: 2022121311132761200_ofac625-B42 article-title: Ba.1 and BA.2 sub-lineages of Omicron variant have comparable replication kinetics and susceptibility to neutralization by antibodies publication-title: MedRxiv – volume: 17 start-page: e0263942 year: 2022 ident: 2022121311132761200_ofac625-B12 article-title: Effect of the third dose of BNT162b2 vaccine on quantitative SARS-CoV-2 spike 1–2 IgG antibody titers in healthcare personnel publication-title: PLoS One doi: 10.1371/journal.pone.0263942 – volume: 13 start-page: 852 year: 2022 ident: 2022121311132761200_ofac625-B4 article-title: Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection publication-title: Nat Commun doi: 10.1038/s41467-022-28544-w – volume: 327 start-page: 179 year: 2022 ident: 2022121311132761200_ofac625-B33 article-title: Antibody response and variant cross-neutralization after SARS-CoV-2 breakthrough infection publication-title: JAMA doi: 10.1001/jama.2021.22898 – volume: 12 start-page: e0265621 year: 2021 ident: 2022121311132761200_ofac625-B13 article-title: Previous infection combined with vaccination produces neutralizing antibodies with potency against SARS-CoV-2 variants publication-title: mBio doi: 10.1128/mBio.02656-21 |
SSID | ssj0001105079 |
Score | 2.2742026 |
Snippet | Abstract
Background
Previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection primes the immune system; thus individuals who have... Previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection primes the immune system; thus individuals who have recovered from infection... Background Previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection primes the immune system; thus individuals who have recovered from... |
SourceID | pubmedcentral proquest pubmed crossref oup |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | ofac625 |
SubjectTerms | Infections Major Severe acute respiratory syndrome coronavirus 2 Vaccines |
SummonAdditionalLinks | – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9QwEB6VIiEuiPJMaZGR4IQMceLEmwOqVoVVQWoPXbb0FtmO3a60SqCbqpTfwI_uTOJd7VY8LokUj5PIM7a_GX8eA7xOlHeJFY6rPPZcZk5y7YqKe-HwKXaoqmdbHOUHE_nlNDvdgMVpo6EB53907eg8qcnF7N3PH9d72OE_hGRI71ELFV60RSx_B-7inJSTfR8GoN9FWxBGxKoIzPfbldbmpLV9bitw8zZrcmUaGj2EBwE_smGv8C3YcPUjuHcYVsgfw-8xxbbP2JG77GIYv3BqYsO6nZqmumbHPSPWzVnbsPHweMz3mxOesBP0mIkQw0ZoFs0V1dFsjLeZwzJLr2Yfm7lj05rhUEOxmzn7Nm3PGaWAIhrt6ts-B4JX_QQmo09f9w94OHGBWyllyyWti9Le3EJU6Mlo7Q0OCSLWslBOxVL7BOGV8hWxOfOBsi4XVWyVsqkstCnSp7BZN7V7DswWCM6sl7mPjdRmMBDe5FWsTGZslioVwdtFm5c2pCOnUzFmZb8snpakoTJoKII3S-nvfRqOv8gxVN9_RHYWui0X5lYiihJCEQ0oglfLYuxptHyia4ftWCYKvbsMEZSM4FlvCssPpTkiYSHSCNSakSwFKIv3ekk9Pe-yeaNDh6NmvP3v33oB9xPaeNERaXZgs724dLsIh1rzsrP0GyR4DfQ priority: 102 providerName: Scholars Portal |
Title | Strong Neutralizing Antibody Responses to SARS-CoV-2 Variants Following a Single Vaccine Dose in Subjects With Previous SARS-CoV-2 Infection |
URI | https://www.ncbi.nlm.nih.gov/pubmed/36519113 https://www.proquest.com/docview/3171176570 https://www.proquest.com/docview/2754858194 https://pubmed.ncbi.nlm.nih.gov/PMC9745780 |
Volume | 9 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3db9MwED-xTkK8IMbXAltlJHhC1uLEiZMnVMqqgbSC2m30LXIch1WakkEyIfgb-KO5S9yuRQJeHCl2PuQ7n-_j5zuAl4EqbWCE5Sr2Sy4jK7m2acFLYfEuLqiiR1tM45Nz-WERLZzDrXGwypVM7AR1URvykR_hPieEIqDGm-uvnKpGUXTVldDYgV0UwUk0gN23x9NPs1svC6oPvkod4h2t9yMkWYGNNjFVx97Yi7bOt22omX-iJTe2n8kDuO_0RjbqCb0Hd2z1EO6eusj4I_g1J5_2Fza1N53v4iduSWxUtcu8Ln6wWY-EtQ1razYfzeZ8XF_wgF2gpUxAGDZBdqi_0zOazfFyZbHP0KvZu7qxbFkxFDHks2nY52V7ySj1E8FnN9_23gG7qsdwPjk-G59wV2mBGyllyyXFQ-lMbioKtGC0LnMUBcLXMlVW-VKXAapVqiwIxRknythYFL5RyoQy1XkaPoFBVVd2H5hJUSkzpYxLP5c6TxJR5nHhqzzKTRQq5cHr1ZxnxqUhp2oYV1kfDg8zolDmKOTBq_Xo6z79xl_GMSTff4YcrGibuXXaZLdc5cGLdTeuMAqb6MriPGaBQqsuQs1JevC0Z4X1h8IYNWAhQg_UFpOsB1D27u2eannZZfFGQw6lpf_s37_1HO4FdOCiA9AcwKD9dmMPUQ1q8yHsqIXCNhmLoeP7YedSwPZUJtiefVz8Bi9kEIo |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fT9swED8hkLa9IPY_wDZPGk-TRZw4cfMwTR1QtQOqqQXGW-Y4DlRCCSxBiH2GfZZ9xt01SWknbXvipZXqaxLlzuef736-A3jnqcx6RliuQjfjMrCSaxulPBMWf8UJldZsi2HYP5afT4PTJfjVnoUhWmXrE6eOOi0Mxci3cZ0TQhFR4-PlFaeuUZRdbVto1Gaxb29vcMtWfhjson63PK-3d7TT501XAW6klBWXlPuj86eRSBGta50laPbC1TJSVrlSZx5CCJWlxFgMO8rYUKSuUcr4MtIJFV9Cl7-CMhHOopVPe8Mvo7uoDsIVV0UNwx5vtI0mkuKHNiF1455b-xbO083B2j_ZmXPLXW8NVhucyrq1YT2GJZs_gQeHTSb-KfwcUwz9jA3t9TRW8gOXQNbNq0lSpLdsVDNvbcmqgo27ozHfKU64x05wZ07EG9ZD8ytu6D-ajfHrwuKYoUuz3aK0bJIzdGkUIyrZ10l1zqjUFNF15682aIhk-TM4vhcdPIflvMjtS2AmQhBoMhlmbiJ10umILAlTVyVBYgJfKQfet-88Nk3Zc-q-cRHX6Xc_Jg3FjYYc2JpJX9blPv4ix1B9_xHZbHUbN36hjO-s2IG3s2Gc0ZSm0bnF9xh7CneRASI16cCL2hRmN_JDRNxC-A6oBSOZCVC18MWRfHI-rRqOG0f0zu76vx_rDTzsHx0exAeD4f4GPPLosMeUvLMJy9X3a_sKIViVvG7snsG3-55qvwFCz0Zi |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Strong+Neutralizing+Antibody+Responses+to+SARS-CoV-2+Variants+Following+a+Single+Vaccine+Dose+in+Subjects+With+Previous+SARS-CoV-2+Infection&rft.jtitle=Open+forum+infectious+diseases&rft.au=Ekstr%C3%B6m%2C+Nina&rft.au=Haveri%2C+Anu&rft.au=Solastie%2C+Anna&rft.au=Virta%2C+Camilla&rft.date=2022-12-01&rft.pub=Oxford+University+Press&rft.eissn=2328-8957&rft.volume=9&rft.issue=12&rft_id=info:doi/10.1093%2Fofid%2Fofac625 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2328-8957&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2328-8957&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2328-8957&client=summon |